Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Bryan Clines
Regulatory Coordinator III
Cancer Center Division
Full Page
Overview
Research
More
Collaboration
(14)
Michael Grandner
Mutual work: 1 Grant
Collaboration Details
Rachna Shroff
Mutual work: 4 Proposals﹒3 Grants
Collaboration Details
Hina Arif Tiwari
Mutual work: 5 Proposals﹒2 Grants
Collaboration Details
Edward Gelmann
Mutual work: 3 Proposals﹒2 Grants
Collaboration Details
Bital Savir-Baruch
Mutual work: 2 Proposals
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(6)
A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Active
·
2024
·
$0 / $2.2M
·
External
prostate cancer,
clinical trial,
treatment comparison,
metastatic cancer,
hormone therapy
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
Active
·
2024
·
$0 / $625.4K
·
External
oncology,
clinical trial,
drug combination,
efficacy,
patient safety
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
Active
·
2023
·
$0 / $684.8K
·
External
cancer treatment,
drug trial,
dose escalation,
solid tumors,
lymphomas
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Active
·
2023
·
$0 / $494.2K
·
External
cancer,
immunotherapy,
clinical trials,
metastasis,
treatment comparison
Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies
Active
·
2023
·
$0 / $432.5K
·
External
gsk-3b inhibitor,
hematologic malignancies,
chemotherapy
Page 1 of 2
Previous page
Next page
